OneMedNet Corporation (ONMDW) 股票分析

公司概述

OneMedNet Corporation operates as a healthcare software provider focused on delivering digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East. The company's core product offering, iRWD, is designed to supply regulatory-grade imaging and clinical data specifically for the pharmaceutical and device manufacturing sectors. Although the specific sector and industry classifications are not publicly disclosed in the available data, the business model indicates a specialization in B2B digital infrastructure for life sciences. The company reports an annual revenue of $1.36 million and a market capitalization that is not currently available, with no disclosed employee count. The absence of a reported market cap figure alongside the modest revenue scale suggests that the firm operates as a micro-cap entity, likely facing significant challenges in achieving the scale necessary to influence broader market pricing or industry standards within its niche.

财务健康

OneMedNet Corporation reported a trailing twelve-month revenue of $1.36 million, yet this generated a net loss of $2,801,000, revealing a cost structure where expenses significantly outpace top-line income. The company's EBITDA stands at a loss of $9,602,000, indicating that operational cash generation before interest and taxes remains deeply negative despite the recorded revenue. Free cash flow is negative at $7,840,750, which implies a lack of financial flexibility as the company is burning cash reserves rather than generating liquidity from operations. The gross margin is negative 37.0%, the operating margin is negative 345.9%, and the profit margin is negative 206.1%, all of which indicate a highly unprofitable business model where costs for sales, operations, and gross delivery are substantially higher than revenue. The balance sheet shows $585,000 in cash against $974,000 in debt, while the debt-to-equity ratio is not available; however, the negative price-to-book ratio of -1.21 suggests assets may be valued below the market price of equity or significant intangible liabilities exist. The current ratio stands at 0.43, indicating that current liabilities exceed current assets, which points to potential short-term liquidity constraints in meeting obligations as they come due. Return on equity is not available, but the return on assets is -205.6%, revealing that management is not currently effective at generating returns on the capital base employed in the business.

估值评估

The trailing P/E ratio and forward P/E ratio are not available due to the company's loss-making status, meaning traditional earnings-based valuation multiples cannot be calculated or imply an infinite P/E multiple given the negative net income. The price-to-book ratio is recorded at -1.21, which indicates an anomaly in valuation metrics where the market price per share is lower than the book value per share, or the book value is negative due to accumulated losses. The price-to-sales ratio and EV/EBITDA are also not available, preventing a comparison against industry peers on these alternative valuation metrics. The 52-week high and low for the stock are both $0.07, suggesting the stock has been trading within a very narrow range with no price discovery or volatility observed within the last year. Since the high and low are identical, the current price sits exactly at the 52-week trading range boundaries, offering no discount or premium relative to the annual price floor or ceiling. The beta value is 1.17, which indicates that the stock's price volatility is 17% higher than the broader market, suggesting higher risk exposure to market fluctuations than a standard equity investment.

Growth & Income

The company experienced a revenue growth year-over-year of 3326.9%, while earnings growth is not available due to the persistent net losses. This divergence implies that while the top line is expanding rapidly, profitability has not yet followed, often characteristic of early-stage technology firms investing heavily in sales and development. As the company does not pay dividends, there is no dividend yield or payout ratio to evaluate, meaning the firm retains all earnings to reinvest into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is defined by explosive top-line expansion coupled with significant cash burn and an absence of current income generation for investors.